首页 > 最新文献

Biomedicine & Pharmacotherapy最新文献

英文 中文
The therapeutic potential of andrographolide in cancer treatment
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-19 DOI: 10.1016/j.biopha.2024.117438

Cancer poses a substantial global health challenge, necessitating the widespread use of chemotherapy and radiotherapy. Despite these efforts, issues like resistance development and severe side effects remain. As such, the search for more effective alternatives is critical. Andrographolide, a naturally occurring compound, has recently gained attention for its extensive biological activities. This review explores the role of andrographolide in cancer therapy, especially focusing on the molecular mechanisms that drive its anti-tumor properties. It also examines innovative methods to enhance andrographolide's bioavailability, thus boosting its effectiveness against cancer. Notably, andrographolide has potential for use in combination with various clinical drugs, and both preclinical and clinical studies provide strong evidence supporting its broader anticancer applications. Additionally, this paper proposes future research directions for andrographolide's anti-cancer effects and discusses the challenges in its clinical usage along with current research efforts to address these issues. In summary, this review underscores andrographolide's potential roles and contributes to the development of improved cancer treatment strategies.

癌症对全球健康构成了巨大挑战,因此必须广泛使用化疗和放疗。尽管做出了这些努力,但抗药性产生和严重副作用等问题依然存在。因此,寻找更有效的替代品至关重要。穿心莲内酯是一种天然化合物,最近因其广泛的生物活性而备受关注。这篇综述探讨了穿心莲内酯在癌症治疗中的作用,尤其侧重于驱动其抗肿瘤特性的分子机制。它还研究了提高穿心莲内酯生物利用度的创新方法,从而增强其抗癌功效。值得注意的是,穿心莲内酯具有与各种临床药物联合使用的潜力,临床前研究和临床研究为其更广泛的抗癌应用提供了有力的证据支持。此外,本文还提出了穿心莲内酯抗癌作用的未来研究方向,并讨论了其临床应用所面临的挑战以及目前为解决这些问题所做的研究工作。总之,本综述强调了穿心莲内酯的潜在作用,并有助于开发更好的癌症治疗策略。
{"title":"The therapeutic potential of andrographolide in cancer treatment","authors":"","doi":"10.1016/j.biopha.2024.117438","DOIUrl":"10.1016/j.biopha.2024.117438","url":null,"abstract":"<div><p>Cancer poses a substantial global health challenge, necessitating the widespread use of chemotherapy and radiotherapy. Despite these efforts, issues like resistance development and severe side effects remain. As such, the search for more effective alternatives is critical. Andrographolide, a naturally occurring compound, has recently gained attention for its extensive biological activities. This review explores the role of andrographolide in cancer therapy, especially focusing on the molecular mechanisms that drive its anti-tumor properties. It also examines innovative methods to enhance andrographolide's bioavailability, thus boosting its effectiveness against cancer. Notably, andrographolide has potential for use in combination with various clinical drugs, and both preclinical and clinical studies provide strong evidence supporting its broader anticancer applications. Additionally, this paper proposes future research directions for andrographolide's anti-cancer effects and discusses the challenges in its clinical usage along with current research efforts to address these issues. In summary, this review underscores andrographolide's potential roles and contributes to the development of improved cancer treatment strategies.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013246/pdfft?md5=55e0265f6c3492e35c427b86a2827c75&pid=1-s2.0-S0753332224013246-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baicalin methyl ester prevents the LPS – induced mice intestinal barrier damage in vivo and in vitro via P65/TNF-α/MLCK/ZO-1 signal pathway
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-18 DOI: 10.1016/j.biopha.2024.117417
<div><p>The effect of baicalin methyl ester (BME) on the regulation of mice intestinal barrier in the inflammatory response was studied in vivo and in vitro. Thirty six C57/BL mice were randomly divided into six groups (n = 6): control group; LPS group (LPS 3.5 mg/kg given intraperitoneal [ip] on day 7 of the study only), PBS group, and three BME groups (low: 50 mg/kg; medium: 100 mg/kg; high: 200 mg/kg) orally dosed with BME for 7d and LPS ip on day 7. All mice were sacrificed on day 8, and jejunum tissue collected for histopathology (H&E and PAS staining), protein expression of pro-inflammatory factors (TNF-α, IL-6, IL-8, IFN-γ) by ELISA, and intestinal tight junction proteins (ZO-1, occludin, claudin-1 and claudin-4) by Western Blot. Compared with the control group, LPS significantly increased the serum cytokines DAO (<em>p</em> < 0.01) and DLA (<em>p</em> < 0.01), u<em>p</em>regulated the expression of pro-inflammatory factors, MLCK proteins (<em>p</em> <0.05) and increased the MLCK/ZO-1ratio (<em>p</em> <0.001). LPS also decreased the expression of claudin-4 (<em>p</em> < 0.01) in the jejunum and induced an inflammatory response damaging the jejunal mucosal barrier. Pretreatment with BME (100–200 mg/kg) significantly decreased the cytokines DAO (<em>p</em> < 0.05) and DLA (<em>p</em> < 0.01) in the serum, pro-inflammatory factors in the jejunum, significantly down-regulated the expression of MLCK (<em>p</em> <0.05) and the ratio of MLCK/ZO-1(<em>p</em> <0.001) but upregulated the expressions of ZO-1(<em>p</em> < 0.01), occludin (<em>p</em> < 0.05), claudin-1(<em>p</em> < 0.05) and claudin-4 (<em>p</em> < 0.05), and thereby restored the intestinal tissue structure, suggestive of alleviation of LPS-induced intestinal inflammation by BME. In vitro, MODE-K cells (derived from mice intestinal epithelium) were exposed to BME at 0 (control group-No LPS), 10, 20 and 40 μM BME for 24 h prior to LPS addition at 50 μg/mL for 2 h. LPS significantly increased the expression of pro-inflammatory factors, MLCK (<em>p</em> < 0.01) and the ratio of MLCK/ZO-1(<em>p</em> <0.001), decreased the expressions of ZO-1 (<em>p</em> < 0.05), occludin (<em>p</em> < 0.01), claudin-1 (<em>p</em> < 0.01) and claudin-4 (<em>p</em> < 0.01) in MODE-K cells compared with the control group. Compared with the LPS group, BME (10 – 40 μM) significantly decreased the expression of pro-inflammatory factors, MLCK (<em>p</em> < 0.05) and the ratio of MLCK/ZO-1(<em>p</em> <0.01) but increased the expressions of ZO-1(<em>p</em> < 0.01), occludin (<em>p</em> < 0.05) and claudin-4(<em>p</em> < 0.01) indicating an up-regulation of the expression of tight junction proteins by BME. On addition of extrinsic TNF-α plus LPS, the TNF- α level increased (<em>p</em> < 0.001) in MODE-K cells and the protein expression of MLCK (<em>p</em> < 0.01) was markedly up-regulated. Molecular docking predicted BME interacted wit
研究了黄芩苷甲酯(BME)在体内和体外对炎症反应中小鼠肠屏障调节作用的影响。将36只C57/BL小鼠随机分为6组(n = 6):对照组、LPS组(LPS 3.5 mg/kg,仅在研究的第7天腹腔注射[ip])、PBS组和3个BME组(低:50 mg/kg;中:100 mg/kg;高:200 mg/kg)。所有小鼠均于第8天处死,采集空肠组织进行组织病理学(H&E和PAS染色)、ELISA检测促炎因子(TNF-α、IL-6、IL-8、IFN-γ)的蛋白表达、Western Blot检测肠道紧密连接蛋白(ZO-1、occludin、claudin-1和claudin-4)。与对照组相比,LPS明显增加了血清细胞因子DAO(p <0.01)和DLA(p <0.01),上调了促炎因子、MLCK蛋白的表达(p <0.05),并增加了MLCK/ZO-1比率(p <0.001)。LPS 还降低了空肠中 claudin-4 蛋白的表达(p <0.01),并诱发了破坏空肠粘膜屏障的炎症反应。用 BME(100-200 mg/kg)预处理可明显降低血清中的细胞因子 DAO(p < 0.05)和 DLA(p < 0.01),它们是空肠中的促炎因子,可明显下调 MLCK 的表达(p < 0.05)和 MLCK/ZO-1 的比值(p < 0.001),但上调了ZO-1(p <0.01)、occludin(p <0.05)、claudin-1(p <0.05)和claudin-4(p <0.05)的表达,从而恢复了肠道组织结构。在体外,将 MODE-K 细胞(来源于小鼠肠上皮细胞)暴露于 0(对照组-无 LPS)、10、20 和 40 μM BME 中 24 小时,然后加入 50 μg/mL LPS 2 小时。与对照组相比,LPS明显增加了MODE-K细胞中促炎因子MLCK(p <0.01)和MLCK/ZO-1比值(p <0.001)的表达,降低了ZO-1(p <0.05)、occludin(p <0.01)、claudin-1(p <0.01)和claudin-4(p <0.01)的表达。与LPS组相比,BME(10 - 40 μM)明显降低了促炎因子MLCK(p <0.05)和MLCK/ZO-1比值(p <0.01)的表达,但增加了ZO-1(p <0.01)、occludin(p <0.05)和claudin-4(p <0.01)的表达,表明BME上调了紧密连接蛋白的表达。加入外源性 TNF-α 和 LPS 后,MODE-K 细胞中 TNF-α 水平升高(p < 0.001),MLCK 蛋白表达明显上调(p < 0.01)。分子对接预测 BME 通过形成氢键与 P65 相互作用。IP-WB进一步证实了BME在MODE-K细胞中直接与P65蛋白结合。总之,BME能够通过P65 / TNF-α / MLCK / ZO-1信号通路恢复肠道屏障。
{"title":"Baicalin methyl ester prevents the LPS – induced mice intestinal barrier damage in vivo and in vitro via P65/TNF-α/MLCK/ZO-1 signal pathway","authors":"","doi":"10.1016/j.biopha.2024.117417","DOIUrl":"10.1016/j.biopha.2024.117417","url":null,"abstract":"&lt;div&gt;&lt;p&gt;The effect of baicalin methyl ester (BME) on the regulation of mice intestinal barrier in the inflammatory response was studied in vivo and in vitro. Thirty six C57/BL mice were randomly divided into six groups (n = 6): control group; LPS group (LPS 3.5 mg/kg given intraperitoneal [ip] on day 7 of the study only), PBS group, and three BME groups (low: 50 mg/kg; medium: 100 mg/kg; high: 200 mg/kg) orally dosed with BME for 7d and LPS ip on day 7. All mice were sacrificed on day 8, and jejunum tissue collected for histopathology (H&amp;E and PAS staining), protein expression of pro-inflammatory factors (TNF-α, IL-6, IL-8, IFN-γ) by ELISA, and intestinal tight junction proteins (ZO-1, occludin, claudin-1 and claudin-4) by Western Blot. Compared with the control group, LPS significantly increased the serum cytokines DAO (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) and DLA (&lt;em&gt;p&lt;/em&gt; &lt; 0.01), u&lt;em&gt;p&lt;/em&gt;regulated the expression of pro-inflammatory factors, MLCK proteins (&lt;em&gt;p&lt;/em&gt; &lt;0.05) and increased the MLCK/ZO-1ratio (&lt;em&gt;p&lt;/em&gt; &lt;0.001). LPS also decreased the expression of claudin-4 (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) in the jejunum and induced an inflammatory response damaging the jejunal mucosal barrier. Pretreatment with BME (100–200 mg/kg) significantly decreased the cytokines DAO (&lt;em&gt;p&lt;/em&gt; &lt; 0.05) and DLA (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) in the serum, pro-inflammatory factors in the jejunum, significantly down-regulated the expression of MLCK (&lt;em&gt;p&lt;/em&gt; &lt;0.05) and the ratio of MLCK/ZO-1(&lt;em&gt;p&lt;/em&gt; &lt;0.001) but upregulated the expressions of ZO-1(&lt;em&gt;p&lt;/em&gt; &lt; 0.01), occludin (&lt;em&gt;p&lt;/em&gt; &lt; 0.05), claudin-1(&lt;em&gt;p&lt;/em&gt; &lt; 0.05) and claudin-4 (&lt;em&gt;p&lt;/em&gt; &lt; 0.05), and thereby restored the intestinal tissue structure, suggestive of alleviation of LPS-induced intestinal inflammation by BME. In vitro, MODE-K cells (derived from mice intestinal epithelium) were exposed to BME at 0 (control group-No LPS), 10, 20 and 40 μM BME for 24 h prior to LPS addition at 50 μg/mL for 2 h. LPS significantly increased the expression of pro-inflammatory factors, MLCK (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) and the ratio of MLCK/ZO-1(&lt;em&gt;p&lt;/em&gt; &lt;0.001), decreased the expressions of ZO-1 (&lt;em&gt;p&lt;/em&gt; &lt; 0.05), occludin (&lt;em&gt;p&lt;/em&gt; &lt; 0.01), claudin-1 (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) and claudin-4 (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) in MODE-K cells compared with the control group. Compared with the LPS group, BME (10 – 40 μM) significantly decreased the expression of pro-inflammatory factors, MLCK (&lt;em&gt;p&lt;/em&gt; &lt; 0.05) and the ratio of MLCK/ZO-1(&lt;em&gt;p&lt;/em&gt; &lt;0.01) but increased the expressions of ZO-1(&lt;em&gt;p&lt;/em&gt; &lt; 0.01), occludin (&lt;em&gt;p&lt;/em&gt; &lt; 0.05) and claudin-4(&lt;em&gt;p&lt;/em&gt; &lt; 0.01) indicating an up-regulation of the expression of tight junction proteins by BME. On addition of extrinsic TNF-α plus LPS, the TNF- α level increased (&lt;em&gt;p&lt;/em&gt; &lt; 0.001) in MODE-K cells and the protein expression of MLCK (&lt;em&gt;p&lt;/em&gt; &lt; 0.01) was markedly up-regulated. Molecular docking predicted BME interacted wit","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013027/pdfft?md5=b2452643e5a7a7b6390a9196678be563&pid=1-s2.0-S0753332224013027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic efficiency of Tamoxifen/Orlistat nanocrystals against solid ehrlich carcinoma via targeting TXNIP/HIF1-α/MMP-9/P27 and BAX/Bcl2/P53 signaling pathways
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-17 DOI: 10.1016/j.biopha.2024.117429

Background

Orlistat (Orli) is an anti-obesity medication that has been approved by the US Food and Drug Administration. It has relatively limited oral bioavailability with promising inhibitory effects on cell proliferation as well as reducing the growth of tumors.

Aims

This investigation was done to evaluate the potential protective effect of Tamoxifen/Orlistat nanocrystals alone or in combination against Solid Ehrlich Carcinoma (SEC) and to clarify the possible underlying influences.

Materials and methods

The liquid antisolvent precipitation technique (bottom-up technology) was utilized to manufacture Orlistat Nanocrystals. To explore potential causes for the anti-tumor action, female Swiss Albino mice bearing SEC were randomly assigned into five equal groups (n = 6). Group 1: Tumor control group, group 2: Tam group: tamoxifen (0.01 g/kg, IP), group 3: Free-Orli group: orlistat (0.24 g/kg, IP), group 4: Nano-Orli: orlistat nanocrystals (0.24 g/kg, IP), group 5: Tam–Nano-Orli: Both doses of Tam and Nano-Orli. All treatments were administered for 16 days.

Key findings

The untreated mice showed development in the tumor volume and weight. As well as histopathology results from these mice revealed many tumor large cells as well as solid sheets of malignant cells. Also, untreated mice showed raised VEGF and TGF-1beta content. Moreover, results of gene expression in the SEC-bearing mice noted upregulation in HIF-1α, MMP-9, Bcl-2, and P27 gene expression and downregulation of TXNIP, BAX, and P53 gene expression. On the other hand, administrated TAM, Free-Orli, Nano-Orli, and a combination of Tam-Nano-Orli distinctly suppressed the tumor effects on estimated parameters with special reference to Tam-Nano-Orli.

Significance

The developed Tamoxifen/Orlistat nanocrystals combination could be considered a promising approach to augment antitumor effects.

背景奥利司他(Orli)是一种抗肥胖药物,已获得美国食品药品管理局批准。本研究旨在评估他莫昔芬/奥利司他纳米晶体单独或联合使用对实体艾氏腺癌(SEC)的潜在保护作用,并阐明可能的潜在影响因素。为了探索奥利司他抗肿瘤作用的潜在原因,将雌性瑞士白化病小鼠随机分为五个等量组(n = 6)。第1组:肿瘤对照组;第2组:Tam组:他莫昔芬(0.01克/千克,IP);第3组:Free-Orli组:奥利司他(0.24克/千克,IP);第4组:Nano-Orli组:奥利司他纳米晶体(0.24克/千克,IP);第5组:Tam-Nano-Orli组:两种剂量的Tam和Nano-Orli。主要研究结果未经治疗的小鼠肿瘤体积和重量均有增加。这些小鼠的组织病理学结果显示出许多肿瘤大细胞以及恶性细胞的实体片。此外,未经处理的小鼠体内血管内皮生长因子和 TGF-1beta 的含量也有所提高。此外,SEC 小鼠的基因表达结果显示,HIF-1α、MMP-9、Bcl-2 和 P27 基因表达上调,TXNIP、BAX 和 P53 基因表达下调。另一方面,服用他莫昔芬、游离奥利司他、纳米奥利司他和他莫昔芬-纳米-奥利司他的复方制剂可明显抑制肿瘤对估计参数的影响,特别是他莫昔芬-纳米-奥利司他。
{"title":"Therapeutic efficiency of Tamoxifen/Orlistat nanocrystals against solid ehrlich carcinoma via targeting TXNIP/HIF1-α/MMP-9/P27 and BAX/Bcl2/P53 signaling pathways","authors":"","doi":"10.1016/j.biopha.2024.117429","DOIUrl":"10.1016/j.biopha.2024.117429","url":null,"abstract":"<div><h3>Background</h3><p>Orlistat (Orli) is an anti-obesity medication that has been approved by the US Food and Drug Administration. It has relatively limited oral bioavailability with promising inhibitory effects on cell proliferation as well as reducing the growth of tumors.</p></div><div><h3>Aims</h3><p>This investigation was done to evaluate the potential protective effect of Tamoxifen/Orlistat nanocrystals alone or in combination against Solid Ehrlich Carcinoma (SEC) and to clarify the possible underlying influences.</p></div><div><h3>Materials and methods</h3><p>The liquid antisolvent precipitation technique (bottom-up technology) was utilized to manufacture Orlistat Nanocrystals. To explore potential causes for the anti-tumor action, female Swiss Albino mice bearing SEC were randomly assigned into five equal groups (n = 6). Group 1: Tumor control group, group 2: Tam group: tamoxifen (0.01 g/kg, IP), group 3: Free-Orli group: orlistat (0.24 g/kg, IP), group 4: Nano-Orli: orlistat nanocrystals (0.24 g/kg, IP), group 5: Tam–Nano-Orli: Both doses of Tam and Nano-Orli. All treatments were administered for 16 days.</p></div><div><h3>Key findings</h3><p>The untreated mice showed development in the tumor volume and weight. As well as histopathology results from these mice revealed many tumor large cells as well as solid sheets of malignant cells. Also, untreated mice showed raised VEGF and TGF-1beta content. Moreover, results of gene expression in the SEC-bearing mice noted upregulation in HIF-1α, MMP-9, Bcl-2, and P27 gene expression and downregulation of TXNIP, BAX, and P53 gene expression. On the other hand, administrated TAM, Free-Orli, Nano-Orli, and a combination of Tam-Nano-Orli distinctly suppressed the tumor effects on estimated parameters with special reference to Tam-Nano-Orli.</p></div><div><h3>Significance</h3><p>The developed Tamoxifen/Orlistat nanocrystals combination could be considered a promising approach to augment antitumor effects.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013143/pdfft?md5=8518ac68cd6cc612f52e595cfe2f35cf&pid=1-s2.0-S0753332224013143-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive review of perioperative factors influencing ferroptosis 围手术期影响铁蛋白沉积的因素综述
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-14 DOI: 10.1016/j.biopha.2024.117375

The perioperative period encompasses all phases of patient care from the decision to perform surgery until full recovery. Ferroptosis, a newly identified type of regulated cell death, influences a wide array of diseases, including those affecting the prognosis and regression of surgical patients, such as ischemia-reperfusion injury and perioperative cognitive dysfunction. This review systematically examines perioperative factors impacting ferroptosis such as surgical trauma-induced stress, tissue hypoxia, anesthetics, hypothermia, and blood transfusion. By analyzing their intrinsic relationships, we aim to improve intraoperative management, enhance perioperative safety, prevent complications, and support high-quality postoperative recovery, ultimately improving patient outcomes.

围手术期包括从决定实施手术到完全康复的所有病人护理阶段。铁蛋白沉积是一种新发现的调节性细胞死亡类型,影响着一系列疾病,包括影响手术患者预后和康复的疾病,如缺血再灌注损伤和围手术期认知功能障碍。这篇综述系统研究了影响铁细胞凋亡的围手术期因素,如手术创伤引起的应激、组织缺氧、麻醉剂、低体温和输血。通过分析这些因素之间的内在关系,我们旨在改善术中管理、提高围手术期安全性、预防并发症并支持高质量的术后恢复,最终改善患者预后。
{"title":"Comprehensive review of perioperative factors influencing ferroptosis","authors":"","doi":"10.1016/j.biopha.2024.117375","DOIUrl":"10.1016/j.biopha.2024.117375","url":null,"abstract":"<div><p>The perioperative period encompasses all phases of patient care from the decision to perform surgery until full recovery. Ferroptosis, a newly identified type of regulated cell death, influences a wide array of diseases, including those affecting the prognosis and regression of surgical patients, such as ischemia-reperfusion injury and perioperative cognitive dysfunction. This review systematically examines perioperative factors impacting ferroptosis such as surgical trauma-induced stress, tissue hypoxia, anesthetics, hypothermia, and blood transfusion. By analyzing their intrinsic relationships, we aim to improve intraoperative management, enhance perioperative safety, prevent complications, and support high-quality postoperative recovery, ultimately improving patient outcomes.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224012605/pdfft?md5=eee926d68ae8ee106aca74d443c0ded7&pid=1-s2.0-S0753332224012605-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Podocan unraveled: Understanding its role in tumor proliferation and smooth muscle regulation 揭开 Podocan 的神秘面纱:了解其在肿瘤增殖和平滑肌调节中的作用
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-13 DOI: 10.1016/j.biopha.2024.117416

Podocan, a small leucine-rich repeat protein, is expressed in HIV-associated nephropathy, the cardiovascular system, and smooth muscle. Studies have linked PODN and PODNL to cancers such as osteosarcoma, glioma, and stomach cancer. Research has primarily focused on podocan's role in renal podocytes, injured smooth muscle cells, and various tumor cells. Bioinformatics studies have examined the role of PODN as a biomarker in tumors. Our research summarizes the modulatory role of podocan in smooth muscle and tumor proliferation through its suppression of cell proliferation and promotion of cell differentiation via various signaling pathways, including Wnt/β-catenin, TGF-β, and Akt/mTOR. We aim to provide a comprehensive overview of PODN's involvement in smooth muscle, cardiovascular system, and tumors by integrating current and past research. This review aims to enhance understanding and inform in the diagnosis, prognosis, and treatment of various diseases.

Podocan 是一种富含亮氨酸的小重复蛋白,在艾滋病毒相关性肾病、心血管系统和平滑肌中均有表达。研究表明,PODN 和 PODNL 与骨肉瘤、胶质瘤和胃癌等癌症有关。研究主要集中于 podocan 在肾脏荚膜细胞、受伤的平滑肌细胞和各种肿瘤细胞中的作用。生物信息学研究探讨了 PODN 在肿瘤中作为生物标记物的作用。我们的研究总结了 podocan 通过各种信号通路(包括 Wnt/β-catenin、TGF-β 和 Akt/mTOR)抑制细胞增殖和促进细胞分化,在平滑肌和肿瘤增殖中的调节作用。我们旨在通过整合当前和过去的研究,全面概述 PODN 在平滑肌、心血管系统和肿瘤中的参与。这篇综述旨在加深人们对各种疾病的理解,并为诊断、预后和治疗提供参考。
{"title":"Podocan unraveled: Understanding its role in tumor proliferation and smooth muscle regulation","authors":"","doi":"10.1016/j.biopha.2024.117416","DOIUrl":"10.1016/j.biopha.2024.117416","url":null,"abstract":"<div><p>Podocan, a small leucine-rich repeat protein, is expressed in HIV-associated nephropathy, the cardiovascular system, and smooth muscle. Studies have linked PODN and PODNL to cancers such as osteosarcoma, glioma, and stomach cancer. Research has primarily focused on podocan's role in renal podocytes, injured smooth muscle cells, and various tumor cells. Bioinformatics studies have examined the role of PODN as a biomarker in tumors. Our research summarizes the modulatory role of podocan in smooth muscle and tumor proliferation through its suppression of cell proliferation and promotion of cell differentiation via various signaling pathways, including Wnt/β-catenin, TGF-β, and Akt/mTOR. We aim to provide a comprehensive overview of PODN's involvement in smooth muscle, cardiovascular system, and tumors by integrating current and past research. This review aims to enhance understanding and inform in the diagnosis, prognosis, and treatment of various diseases.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013015/pdfft?md5=47643939a3ee3bbc4c69944de1383d1f&pid=1-s2.0-S0753332224013015-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment 肿瘤浸润 B 细胞:它们在肿瘤微环境中的双重机制作用
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-12 DOI: 10.1016/j.biopha.2024.117436

The occurrence and development of tumors are closely associated with abnormalities in the immune system's structure and function, with tumor immunotherapy being intricately linked to the tumor microenvironment (TME). Early studies on lymphocytes within the TME primarily concentrated on T cells. However, as research has advanced, the multifaceted roles of tumor-infiltrating B cells (TIL-Bs) in tumor immunity, encompassing both anti-tumor and pro-tumor effects, have garnered increasing attention. This paper explored the composition of the TME and the biological characteristics of TIL-Bs, investigating the dual roles within the TME to offer new insights and strategies for tumor immunotherapy.

肿瘤的发生和发展与免疫系统的结构和功能异常密切相关,而肿瘤免疫疗法与肿瘤微环境(TME)密切相关。早期对肿瘤微环境中淋巴细胞的研究主要集中在 T 细胞上。然而,随着研究的深入,肿瘤浸润 B 细胞(TIL-Bs)在肿瘤免疫中的多方面作用(包括抗肿瘤和促肿瘤作用)日益受到关注。本文探讨了TME的组成和TIL-Bs的生物学特性,研究了TME内的双重作用,为肿瘤免疫疗法提供新的见解和策略。
{"title":"Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment","authors":"","doi":"10.1016/j.biopha.2024.117436","DOIUrl":"10.1016/j.biopha.2024.117436","url":null,"abstract":"<div><p>The occurrence and development of tumors are closely associated with abnormalities in the immune system's structure and function, with tumor immunotherapy being intricately linked to the tumor microenvironment (TME). Early studies on lymphocytes within the TME primarily concentrated on T cells. However, as research has advanced, the multifaceted roles of tumor-infiltrating B cells (TIL-Bs) in tumor immunity, encompassing both anti-tumor and pro-tumor effects, have garnered increasing attention. This paper explored the composition of the TME and the biological characteristics of TIL-Bs, investigating the dual roles within the TME to offer new insights and strategies for tumor immunotherapy.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013222/pdfft?md5=76f9a880a55c32eebd04ab7ee6428a57&pid=1-s2.0-S0753332224013222-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron chelators as mitophagy agents: Potential and limitations 作为有丝分裂剂的铁螯合剂:潜力和局限性
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-11 DOI: 10.1016/j.biopha.2024.117407

Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.

线粒体自噬(mitophagy)是维持细胞平衡、功能和存活的重要过程。它的失调与许多严重疾病(如肿瘤、神经退行性疾病和心血管疾病)的高风险和进展有关。因此,针对有丝分裂机制的研究是生物学和医学研究的热门话题。有丝分裂的调控与铁稳态之间的相互关系现在变得越来越明显。简而言之,线粒体是调节铁平衡的中心点,而细胞内可欺骗铁水平的变化可诱导/抑制有丝分裂。在这篇综述中,对铁稳态和有丝分裂之间的关系进行了深入的讨论和描述。此外,还对有丝分裂螯合剂在个别疾病中的治疗适用性进行了全面而严谨的评估。
{"title":"Iron chelators as mitophagy agents: Potential and limitations","authors":"","doi":"10.1016/j.biopha.2024.117407","DOIUrl":"10.1016/j.biopha.2024.117407","url":null,"abstract":"<div><p>Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224012927/pdfft?md5=6da4c3dc73d33554b9faa7859c8ec76f&pid=1-s2.0-S0753332224012927-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer CTLA-4 免疫检查点抑制剂在胰腺癌中的应用进展
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-10 DOI: 10.1016/j.biopha.2024.117430

Targeting checkpoints for immune cell activation has been acknowledged known as one of the most effective way to activate anti-tumor immune responses. Among them, drugs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are approved for clinical treatment though several more are in advanced stages of development, which demonstrated durable response rates and manageable safety profile. However, its therapy efficacy is unsatisfactory in pancreatic cancer (PC), which can be limited by the overall condition of patients, the pathological type of PC, the expression level of tumor related genes, etc. To improve clinical efficiency, various researches have been conducted, and the efficacy of combination therapy showed significantly improvement compared to monotherapy. This review analyzed current strategies based on anti-CTLA-4 combination immunotherapy, providing totally new idea for future research.

靶向检查点激活免疫细胞已被公认为激活抗肿瘤免疫反应的最有效方法之一。其中,以细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4)为靶点的药物已被批准用于临床治疗,还有几种药物正处于开发的后期阶段,这些药物显示出持久的应答率和可控的安全性。然而,其对胰腺癌(PC)的疗效并不理想,这可能受到患者整体情况、PC 病理类型、肿瘤相关基因表达水平等因素的限制。为了提高临床疗效,人们开展了各种研究,与单药治疗相比,联合治疗的疗效显著提高。本综述分析了目前基于抗CTLA-4联合免疫疗法的策略,为今后的研究提供了全新的思路。
{"title":"Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer","authors":"","doi":"10.1016/j.biopha.2024.117430","DOIUrl":"10.1016/j.biopha.2024.117430","url":null,"abstract":"<div><p>Targeting checkpoints for immune cell activation has been acknowledged known as one of the most effective way to activate anti-tumor immune responses. Among them, drugs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are approved for clinical treatment though several more are in advanced stages of development, which demonstrated durable response rates and manageable safety profile. However, its therapy efficacy is unsatisfactory in pancreatic cancer (PC), which can be limited by the overall condition of patients, the pathological type of PC, the expression level of tumor related genes, etc. To improve clinical efficiency, various researches have been conducted, and the efficacy of combination therapy showed significantly improvement compared to monotherapy. This review analyzed current strategies based on anti-CTLA-4 combination immunotherapy, providing totally new idea for future research.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013155/pdfft?md5=32755b7149ee8c79ed3040f7cf10c3fc&pid=1-s2.0-S0753332224013155-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in a novel model of autophagy and immune network regulation in radioresistance of cancer stem cells 癌症干细胞放射抗性中自噬和免疫网络调控新模型的研究进展
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-09 DOI: 10.1016/j.biopha.2024.117420

Radiotherapy, a precise modality for treating malignant tumors, has undergone rapid advancements in primary and clinical research. The mechanisms underlying tumor radioresistance have become significant research. With the introduction and in-depth study of cancer stem cells (CSCs) theory, CSCs have been identified as the primary factor contributing to the development of tumor radioresistance. The “stemness” of CSCs is a biological characteristic of a small subset of cells within tumor tissues, characterized by self-renewal solid ability. This characteristic leads to resistance to radiotherapy, chemotherapy, and targeted therapies, driving tumor recurrence and metastasis. Another study revealed that cellular autophagy plays a pivotal role in maintaining the “stemness” of CSCs. Autophagy is a cellular mechanism that degrades proteins and organelles to generate nutrients and energy in response to stress. This process maintains cellular homeostasis and contributes to CSCs radioresistance. Furthermore, ionizing radiation (IR) facilitates epithelial-to-mesenchymal transition (EMT), vascular regeneration, and other tumor processes by influencing the infiltration of M2-type tumor-associated macrophages (TAMs). IR promotes the activation of the classical immunosuppressive “switch,” PD-1/PD-L1, which diminishes T-cell secretion, leading to immune evasion and promoting radioresistance. Interestingly, recent studies have found that the immune pathway PD-1/PD-L1 is closely related to cellular autophagy. However, the interrelationships between immunity, autophagy, and radioresistance of CSCs and the regulatory mechanisms involved remain unclear. Consequently, this paper reviews recent research to summarize these potential connections, aiming to establish a theoretical foundation for future studies and propose a new model for the network regulation of immunity, autophagy, and radioresistance of tumor cells.

放疗作为一种治疗恶性肿瘤的精确方法,在基础研究和临床研究方面取得了突飞猛进的发展。肿瘤放射耐药的机制已成为重要的研究课题。随着癌症干细胞(CSCs)理论的提出和深入研究,CSCs 被认为是导致肿瘤放射抗性发生的主要因素。CSCs的 "干性 "是肿瘤组织内一小部分细胞的生物学特征,具有自我更新的固态能力。这一特性导致对放疗、化疗和靶向治疗的耐药性,推动肿瘤复发和转移。另一项研究显示,细胞自噬在维持CSCs的 "干性 "方面发挥着关键作用。自噬是一种细胞机制,可降解蛋白质和细胞器,以产生营养和能量来应对压力。这一过程可维持细胞稳态,并有助于增强CSCs的抗辐射能力。此外,电离辐射(IR)通过影响 M2 型肿瘤相关巨噬细胞(TAMs)的浸润,促进上皮细胞向间质转化(EMT)、血管再生和其他肿瘤过程。IR会促进经典免疫抑制 "开关 "PD-1/PD-L1的激活,从而减少T细胞的分泌,导致免疫逃避并促进放射抵抗。有趣的是,最近的研究发现,免疫途径 PD-1/PD-L1 与细胞自噬密切相关。然而,免疫、自噬和 CSCs 放射抗性之间的相互关系及其调控机制仍不清楚。因此,本文回顾了最近的研究,总结了这些潜在的联系,旨在为今后的研究奠定理论基础,并提出免疫、自噬和肿瘤细胞放射抗性网络调控的新模型。
{"title":"Advancements in a novel model of autophagy and immune network regulation in radioresistance of cancer stem cells","authors":"","doi":"10.1016/j.biopha.2024.117420","DOIUrl":"10.1016/j.biopha.2024.117420","url":null,"abstract":"<div><p>Radiotherapy, a precise modality for treating malignant tumors, has undergone rapid advancements in primary and clinical research. The mechanisms underlying tumor radioresistance have become significant research. With the introduction and in-depth study of cancer stem cells (CSCs) theory, CSCs have been identified as the primary factor contributing to the development of tumor radioresistance. The “stemness” of CSCs is a biological characteristic of a small subset of cells within tumor tissues, characterized by self-renewal solid ability. This characteristic leads to resistance to radiotherapy, chemotherapy, and targeted therapies, driving tumor recurrence and metastasis. Another study revealed that cellular autophagy plays a pivotal role in maintaining the “stemness” of CSCs. Autophagy is a cellular mechanism that degrades proteins and organelles to generate nutrients and energy in response to stress. This process maintains cellular homeostasis and contributes to CSCs radioresistance. Furthermore, ionizing radiation (IR) facilitates epithelial-to-mesenchymal transition (EMT), vascular regeneration, and other tumor processes by influencing the infiltration of M2-type tumor-associated macrophages (TAMs). IR promotes the activation of the classical immunosuppressive “switch,” PD-1/PD-L1, which diminishes T-cell secretion, leading to immune evasion and promoting radioresistance. Interestingly, recent studies have found that the immune pathway PD-1/PD-L1 is closely related to cellular autophagy. However, the interrelationships between immunity, autophagy, and radioresistance of CSCs and the regulatory mechanisms involved remain unclear. Consequently, this paper reviews recent research to summarize these potential connections, aiming to establish a theoretical foundation for future studies and propose a new model for the network regulation of immunity, autophagy, and radioresistance of tumor cells.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224013052/pdfft?md5=ae497e5fb1c8746c3e8521355c22cd49&pid=1-s2.0-S0753332224013052-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging role of tumor microenvironmental nutrients and metabolic molecules in ferroptosis: Mechanisms and clinical implications 肿瘤微环境营养物质和代谢分子在铁凋亡中的新作用:机制和临床意义
IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-09-09 DOI: 10.1016/j.biopha.2024.117406

In recent years, ferroptosis has gradually attracted increasing attention because of its important role in tumors. Ferroptosis resistance is an important cause of tumor metastasis, recurrence and drug resistance. Exploring the initiating factors and specific mechanisms of ferroptosis has become a key strategy to block tumor progression and improve drug sensitivity. As the external space in direct contact with tumor cells, the tumor microenvironment has a great impact on the biological function of tumor cells. The relationships between abnormal environmental characteristics (hypoxia, lactic acid accumulation, etc.) in the microenvironment and ferroptosis of tumor cells has not been fully characterized. This review focuses on the characteristics of the tumor microenvironment and summarizes the mechanisms of ferroptosis under different environmental factors, aiming to provide new insights for subsequent targeted therapy. Moreover, considering the presence of anticancer drugs in the microenvironment, we further summarize the mechanisms of ferroptosis to provide new strategies for the sensitization of tumor cells to drugs.

近年来,铁蛋白沉积症因其在肿瘤中的重要作用而逐渐受到越来越多的关注。高铁血症耐药是肿瘤转移、复发和耐药的重要原因。探索铁凋亡的启动因子和特异机制已成为阻断肿瘤进展、提高药物敏感性的关键策略。肿瘤微环境作为与肿瘤细胞直接接触的外部空间,对肿瘤细胞的生物学功能影响巨大。微环境中的异常环境特征(缺氧、乳酸积聚等)与肿瘤细胞铁突变之间的关系尚未完全定性。本综述将重点关注肿瘤微环境的特征,并总结不同环境因素下的铁突变机制,旨在为后续的靶向治疗提供新的见解。此外,考虑到微环境中存在抗癌药物,我们进一步总结了铁凋亡的机制,为肿瘤细胞对药物的敏感性提供新的策略。
{"title":"Emerging role of tumor microenvironmental nutrients and metabolic molecules in ferroptosis: Mechanisms and clinical implications","authors":"","doi":"10.1016/j.biopha.2024.117406","DOIUrl":"10.1016/j.biopha.2024.117406","url":null,"abstract":"<div><p>In recent years, ferroptosis has gradually attracted increasing attention because of its important role in tumors. Ferroptosis resistance is an important cause of tumor metastasis, recurrence and drug resistance. Exploring the initiating factors and specific mechanisms of ferroptosis has become a key strategy to block tumor progression and improve drug sensitivity. As the external space in direct contact with tumor cells, the tumor microenvironment has a great impact on the biological function of tumor cells. The relationships between abnormal environmental characteristics (hypoxia, lactic acid accumulation, etc.) in the microenvironment and ferroptosis of tumor cells has not been fully characterized. This review focuses on the characteristics of the tumor microenvironment and summarizes the mechanisms of ferroptosis under different environmental factors, aiming to provide new insights for subsequent targeted therapy. Moreover, considering the presence of anticancer drugs in the microenvironment, we further summarize the mechanisms of ferroptosis to provide new strategies for the sensitization of tumor cells to drugs.</p></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0753332224012915/pdfft?md5=a023cfe7f735427152ca773c4478179d&pid=1-s2.0-S0753332224012915-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomedicine & Pharmacotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1